Related references
Note: Only part of the references are listed.Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
Huajia Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
Jian-Guo Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti et al.
EUROPEAN JOURNAL OF CANCER (2021)
High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy
Edmund K. Bartlett et al.
CANCER (2020)
Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy
Adi Kartolo et al.
IMMUNOTHERAPY (2020)
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
Andressa S. Laino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis
Feng Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
Platelet to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer undergoing palliative treatment
Weiwei Gui et al.
ANNALS OF PALLIATIVE MEDICINE (2020)
Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma
Hiroyuki Ohashi et al.
DRUG DISCOVERIES AND THERAPEUTICS (2020)
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
Alessandro Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals
Wanying Guo et al.
CANCER MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
Michele Guida et al.
CANCERS (2019)
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Mehmet A. Bilen et al.
CANCER (2019)
Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
Rachel Howard et al.
SCIENTIFIC REPORTS (2019)
Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis
Hui Zhan et al.
CLINICA CHIMICA ACTA (2018)
High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma
Margaux Garnier et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Role of platelets and platelet receptors in cancer metastasis
Martin Schlesinger
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab (vol 27, pg 732, 2016)
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2018)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Neutrophils in cancer: prognostic role and therapeutic strategies
Alberto Ocana et al.
MOLECULAR CANCER (2017)
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Michael R. Cassidy et al.
EBIOMEDICINE (2017)
Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
Josee-Lyne Ethier et al.
BREAST CANCER RESEARCH (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy
Yi Miao et al.
CANCER BIOMARKERS (2016)
How neutrophils promote metastasis
Thomas Tueting et al.
SCIENCE (2016)
Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
Wencong Ma et al.
SCIENTIFIC REPORTS (2016)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy
Valerie Chew et al.
JOURNAL OF ONCOLOGY (2012)
Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Armen Yuri Gasparyan et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
